Association of inflammatory gene polymorphisms with ischemic stroke in a Chinese Han population by Nan Zhao et al.
RESEARCH Open Access
Association of inflammatory gene polymorphisms
with ischemic stroke in a Chinese Han population
Nan Zhao1†, Xin Liu2,3†, Yongqin Wang2, Xiaoqiu Liu1, Jiana Li1, Litian Yu4, Liyuan Ma4, Shuyu Wang2,
Hongye Zhang2, Lisheng Liu2, Jingbo Zhao1* and Xingyu Wang2,3*
Abstract
Background: Inflammatory mechanisms are important in stroke risk, and genetic variations in components of the
inflammatory response have been implicated as risk factors for stroke. We tested the inflammatory gene
polymorphisms and their association with ischemic stroke in a Chinese Han population.
Methods: A total of 1,124 ischemic stroke cases and 1,163 controls were genotyped with inflammatory panel strips
containing 51 selected inflammatory gene polymorphisms from 35 candidate genes. We tested the
genotype-stroke association with logistic regression model.
Results: We found two single nucleotide polymorphisms (SNPs) in CCL11 were associated with ischemic stroke.
After adjusting for multiple testing using false discovery rate (FDR) with a 0.20 cut-off point, CCL11 rs4795895
remained statistically significant. We further stratified the study population by their hypertension status. In the
hypertensive group, CCR2 rs1799864, CCR5 rs1799987 and CCL11 rs4795895 were nominally associated with
increased risk of stroke. In the non-hypertensive group, CCL11 rs3744508, LTC4S rs730012, FCER1B rs569108, TGFB1
rs1800469, LTA rs909253 and CCL11 rs4795895 were associated with ischemic stroke. After correction for multiple
testing, CCR2 rs1799864 and CCR5 rs1799987 remained significant in the hypertensive group, and CCL11 rs3744508,
LTC4S rs730012, FCER1B rs569108, TGFB1 rs1800469, LTA rs909253 remained significant in the non-hypertensive group.
Conclusions: Our results indicate that inflammatory genetic variants are associated with increased risk of ischemic
stroke in a Chinese Han population, particularly in non-hypertensive individuals.
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Background
Stroke is one of the most common causes of mortality
and a leading cause of adult disability worldwide [1]. In
China, stroke is the leading cause of death, and ischemic
stroke accounts for two-thirds of all strokes [2]. To date,
although the etiology and mechanisms of stroke have
not been well understood, it is considered as a complex
multifactorial disorder with an interaction between the
individual’s genetic background and various environ-
mental factors. Previous studies have demonstrated that
high blood pressure, smoking, poor diet, abdominal
obesity, and lack of physical activities as five common
risk factors associated with 80% of all strokes [3]. How-
ever, these conventional stroke risk factors do not fully
account for the overall risk of stroke. Growing evidence
suggests inflammatory processes play fundamental roles
in both the etiology and pathophysiology of ischemic
cerebrovascular disease [4]. Inflammatory molecules, as
well as single nucleotide polymorphisms (SNPs) of genes
encoding inflammatory mediators, contribute to the de-
velopment and progression of a large number of patho-
logical conditions, including cardiovascular diseases [5].
SNPs of inflammatory genes strongly influence the
plasma levels and biological activity of the corresponding
proteins, with potentially important clinical implications
[6,7]. In this study, we investigated the association be-
tween history of ischemic stroke and polymorphisms of
genes encoding prototypical inflammatory molecules,
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such as interleukin 4 (IL-4), interleukin 6 (IL-6), intercel-
lular adhesion molecule 1 (ICAM-1), E-selectin (E-sel),
chemokine (C-C motif ) ligand 11 (CCL11), lymphotoxin
α (LTA), and so on.
Although hypertension is the most significant risk fac-
tor for stroke [3], evidence from animal and human
studies has indicated that some genes predisposing to is-
chemic stroke are independent of blood pressure [8]. In
order to better control the confounding effect of blood
pressure in ischemic stroke, the case and control sub-
jects were stratified by their hypertension status.
Materials and methods
Study participants
The Stroke Hypertension INvestigation IN Genetics
(SHINING) study was conducted by Beijing Hyperten-
sion League Institute from 1997 to 2000. SHINING
study comprised of subjects exclusive to Han ethnicity.
A total of 3,119 participants (1,559 stroke cases and
1,560 controls) were recruited from 6 geographical
regions in northern China. Cases were recruited from
the community of those who were discharged from hos-
pitals between 1997 to 2000; any stroke patients who
suffered a stroke within the past 5 years were eligible to
participate the study. All patients had to have medical
records with diagnosis from brain computed tomog-
raphy (CT)/MRI. Control subjects were selected accord-
ing to the case–control study criteria during the same
period (control subjects matched to cases by sex, age
within 3 years, geographic location, and blood pressure
category (<140/90, ≥140/90 and ≤180/105, >180/
105 mmHg)). Details of the protocol have been
described elsewhere [9]. Cases with a prior history of
myocardial infarction as well as controls with a previous
history of myocardial infarction or stroke were excluded.
In this study, we focused only on ischemic stroke
(1,124 ischemic stroke cases and 1,163 controls) since it
is the most prevalent form of stroke that accounts for
more than three-quarters of all cases. Data collected
included age, sex, body mass index (BMI), systolic blood
pressure (SBP), diastolic blood pressure (DBP) and
hypertension. Blood pressures were either measured
(one to three measurements) or extracted from medical
records. Hypertension was defined as systolic blood
pressure ≥140 mmHg or diastolic blood pressure
≥90 mmHg or using of antihypertensive medication.
All participants had signed written informed consent
and the study was approved by the ethics committee of
Beijing Hypertension League Institute.
Selection of SNPs and genotyping
DNA was extracted from the whole blood with salting out
procedure. We used a polymerase chain reaction (PCR)-
based inflammatory marker panel (Roche Molecular
Biochemicals, Basel, Switzerland) to genotype DNA sam-
ples. Basic information on the selected SNPs is shown in
Additional file 1: Table S1. These SNPs are not in linkage
disequilibrium. The linkage disequilibrium calculation was
performed using Haploview 4.1 software. The SNPs on
the strip system represent a selection of genetic variants,
essentially all of which had been associated with inflam-
matory diseases before the development of the strips. The
detailed genotyping procedure was described previously
[9]. In brief, multilocus PCR was carried out in a single
tube containing 51 pairs of biotinylated primers. Each
amplified PCR product was hybridized with sequence-
specific oligoprobes immobilized on a nylon membrane
strip; biotin-based color was developed and captured with
a scanner and proprietary software developed by Roche
Molecular Systems. Genotyping calls were made by two
researchers to yield unanimous results. The call rates of
SNPs were more than 98%.
Statistical analysis
Continuous variables were expressed as mean±SD and
differences between case and control groups were ana-
lyzed by Student’s t test. Categorical variables were pre-
sented as percentage. The χ2 or exact test was used to
identify significant departure from Hardy-Weinberg equi-
librium. Polymorphisms with a minor allele frequency
(MAF) <5% would be excluded from the analyses.
Logistic regression models were used to estimate odds
ratios (ORs) and their 95 percent confidence intervals
(95% CIs) by using an additive genetic model. An addi-
tive model was built that assumed that the risk for car-
riers of the heterozygous genotype for developing the
outcome was half way between carriers of the homozy-
gous genotypes. The advantage was that the strength of
genotype-phenotype association was expressed in a sin-
gle parameter (best estimate) and statistical tests had
only 1 degree of freedom [10]. Also this model would
have sufficient power to capture dominant modes of
transmission given our sample size. In a first step, age-
adjusted and sex-adjusted models were constructed.
Thereafter, we fitted multivariable models adjusting for
age, sex, BMI and hypertension status. Given the similar-
ity of the results, only multivariable adjusted models are
presented in this manuscript. To adjust for multiple hy-
pothesis testing, the false discovery rate (FDR) was ap-
plied [11]. The FDR significance threshold was defined
with a value of 0.20 [12], meaning that one should ex-
pect at most 20% of declared discoveries to be false. A
multivariate analysis was performed to find interactions
between polymorphisms and hypertension status, adjust-
ing for age, sex, BMI. All analyses were performed using
SAS V.9.1.3 (SAS, Cary, NC, USA).
Power calculations were generated using a log-additive
model of risk, 5% type 1 error rate. For a minor allele
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frequency of 0.05, the power in the discovery phase of
total group was 86.46%; the power in the hypertension
group was 65.50%; and in non-hypertension the power
was 57.34%. Power calculations were performed using
Quanto software (http://hydra.usc.edu/gxe/).
Results
The baseline and clinical characteristics of study partici-
pants are presented in Table 1. There were 1,124 ische-
mic stroke cases and 1,163 controls in this study. The
control group was older than the case group. There were
more individuals with hypertension in the control group
and BMI was slightly higher compared to the case
group.
Among the 51 polymorphisms, 11 SNPs had a MAF
<5%. Two SNPs (interleukin 4 (IL4) rs2243250
(P= 0.001) and nitric oxide synthase 3 (endothelial cell)
(NOS3) rs1800779 (P= 0.012)) deviated from Hardy-
Weinberg equilibrium (HWE) in the control group and
were excluded from subsequent analysis. Thus, 38 SNPs
were selected for further analysis (see Additional file 1:
Table S1).
As shown in Table 2, two SNPs in CCL11 were asso-
ciated with ischemic stroke (P <0.05) in total study
population. The ORs (95% CI; P value) were 1.47 (1.13 -
1.92; 0.004) for CCL11 rs4795895 and 1.20 (1.01-1.43;
0.042) for CCL11 rs3744508. After adjustment for mul-
tiple testing, CCL11 rs4795895 remained significant
(FDR= 0.152).
Hypertension is a major risk factor for stroke. Evi-
dence has shown that stroke patients with or without
hypertension exhibited different clinical features and dif-
ferent pathophysiology [13]. In consideration of the po-
tential effect, hypertension stratification was decided on
a priori. Odds ratios for the incidence of ischemic stroke
are shown in Table 3. After stratification by hypertension
and adjustment for age, sex, and BMI, 3 of 38 SNPs
showed significant association (P <0.05) with ischemic
stroke in the hypertensive group. These SNPs were in
chemokine (C-C motif ) receptor 2 (CCR2), chemokine
(C-C motif ) receptor 5 (CCR5) and CCL11. The ORs
(95% CI; P value) were 1.26 (1.06 - 1.49; 0.009) for CCR2
rs1799864, 1.23 (1.06 - 1.42; 0.007) for CCR5 rs1799987
and 1.45 (1.05 - 1.99; 0.023) for CCL11 rs4795895. The
FDR values were 0.152, 0.152 and 0.291, respectively.
In the non-hypertensive group, after adjustment for
age, sex and BMI, there were six SNPs associated with
stroke. The ORs (95% CI; P value) of these SNPs were
1.64 (1.20 - 2.24; 0.002) for CCL11 rs3744508, 1.56
(1.14 - 2.14; 0.006) for leukotriene C4 synthase (LTC4S)
rs730012, 1.48 (1.02 - 2.00; 0.009) for FcepsilonRI-β
(FCER1B) rs569108, 1.28 (1.03 - 1.59; 0.028) for lympho-
toxin α (LTA) rs909253, 1.30 (1.07 - 1.59; 0.009) for
transforming growth factor β1 (TGFB1) rs1800469 and
1.67 (1.05 - 2.66; 0.032) for CCL11 rs4795895. After cor-
rection for multiple testing, five SNPs, CCL11 rs3744508,
LTC4S rs730012, FCER1B rs569108, TGFB1 rs1800469,
LTA rs909253, had FDR values less than 0.20 (Table 3).
We tested the interaction between hypertension and gen-
etic variants. There was no interaction detected between
any genetic variants and hypertension status (data not
shown).
Discussion
In this case–control study, we assessed the relationship
of 51 SNPs in 35 genes related to inflammatory response
with the risk of ischemic stroke in 1,124 cases and 1,163
controls. In the control group, there were more indivi-
duals with hypertension and BMI was slightly higher
compared to the case group. This was due to our effort
to recruit controls to match the cases with blood pres-
sure in the search for genes predisposing to ischemic
stroke with and without the influence of hypertension.
Initial analysis showed that CCL11 rs4795895 and
CCL11 rs3744508 were significantly associated with is-
chemic stroke by adjusting for age, sex, BMI and hyper-
tension status, and after adjusting for multiple testing by
FDR, CCL11 rs4795895 remained significantly associated
with ischemic stroke. The CCL11 rs4795895 genetic
polymorphism was the only SNP that retained significant
association with ischemic stroke in the whole group.
After stratification by hypertension, SNP rs4795895 was
still significant in both the non-hypertensive and hyper-
tensive groups, though after adjusting for the multiple
hypothesis test it was not significantly associated with is-
chemic stroke. Polymorphisms rs4795895 and rs3744508
were located in the 5′ flanking region and the coding re-
gion of the eotaxin 1 gene, respectively [14]. Previous
reports have noted that the presence of the CCL11
rs3744508 A allele is associated with lower CCL11 pro-
duction [15] and an increased risk of myocardial infarc-
tion [16]. Ours is the first study to report any
association with SNPs of CCL11 and ischemic stroke.
There are two possible mechanisms by which eotaxin
Table 1 Characteristics of study participants
Ischemic stroke patients Controls P value
Number of subjects 1,124 1,163
Age, mean (SD), years 59.20 (10.71) 62.32 (10.68) <0.0001
Male, % 59.82 61.25 0.483
BMI, mean (SD), kg/m2 24.42 (3.00) 25.04 (3.28) <0.0001
Hypertension, % 64.74 70.19 0.005
Data presented as percentage of participants unless otherwise stated. P values
for χ2 test for categorical variables, and Student’s t test for continuous
variables. Hypertension: systolic blood pressure ≥140 mmHg and/or diastolic
blood pressure ≥90 mmHg, or current treatment with antihypertensive
medication.
BMI = body mass index.
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OR 95% CI P value
CCL11 rs4795895 A G 0.05:0.07 1.47 1.13 - 1.92 0.004 0.152
CCL11 rs3744508 A A 0.14:0.12 1.2 1.01 -1.43 0.042 0.547
CCR5 rs1799987 A A 0.46:0.43 1.13 1.00 - 1.27 0.051 0.547
TGFB1 rs1800469 C C 0.48:0.49 0.9 0.80 - 1.11 0.071 0.547
NOS3 rs1799983 T G 0.10:0.11 1.19 0.99 - 1.45 0.072 0.547
CCR2 rs1799864 A A 0.27:0.25 1.11 0.97 - 1.27 0.143 0.614
IL6 rs1800796 G G 0.33:0.31 1.1 0.97 - 1.25 0.144 0.614
IL4R rs1801275 G G 0.17:0.16 1.12 0.96 - 1.32 0.162 0.614
ADRB2 rs1042713 G G 0.44:0.42 1.09 0.96 - 1.23 0.172 0.614
CD14 rs2569190 T T 0.37:0.38 1.09 0.96 - 1.23 0.187 0.614
TNF rs361525 A A 0.05:0.05 1.2 0.90 - 1.61 0.208 0.614
FCERB1 rs569108 G G 0.17:0.16 1.11 0.94 - 1.30 0.217 0.614
LTA rs909253 G G 0.42:0.41 1.08 0.95 - 1.22 0.227 0.614
IL1A rs1800587 T C 0.09:0.10 1.12 0.92 - 1.37 0.258 0.614
LTC4S rs730012 C C 0.15:0.14 1.1 0.93 - 1.30 0.263 0.614
ADRB2 rs1042714 G G 0.07:0.11 1.11 0.92 - 1.34 0.267 0.614
VDR rs2228570 T T 0.45:0.43 1.15 0.89 - 1.49 0.282 0.614
IL10 rs1800872 C A 0.35:0.36 1.07 0.95 - 1.21 0.291 0.614
GC rs7041 G G 0.27:0.26 1.07 0.94 - 1.23 0.321 0.642
VDR rs1544410 A A 0.06:0.05 1.05 0.94 - 1.19 0.387 0.735
IL5RA rs2290608 A A 0.24:0.23 1.06 0.92 - 1.22 0.435 0.787
IL1B rs16944 T T 0.49:0.47 1.05 0.93 - 1.18 0.456 0.788
TNF rs1800629 A A 0.06:0.06 1.09 0.86 - 1.39 0.478 0.79
CTLA4 rs5742909 T C 0.13:0.14 1.06 0.89 - 1.26 0.528 0.81
CSF2 rs25882 T C 0.38:0.39 1.04 0.92 - 1.17 0.533 0.81
TCF7 rs244656 T A 0.12:0.13 1.04 0.87 - 1.25 0.649 0.856
IL4R rs1805015 C C 0.08:0.08 1.05 0.84 - 1.30 0.669 0.856
SELP rs6131 A A 0.19:0.20 1.03 0.89 - 1.20 0.674 0.856
IL13 rs1295686 T C 0.28:0.29 1.03 0.90 - 1.17 0.679 0.856
VCAM1 rs1041163 C T 0.15:0.16 1.03 0.88 - 1.21 0.687 0.856
CXCL12 rs1801157 A G 0.21:0.22 1.03 0.89 - 1.19 0.698 0.856
CTLA4 rs231775 A G 0.31:0.31 1.02 0.90 - 1.16 0.738 0.876
C5 rs17611 G G 0.42:0.42 1.02 0.90 - 1.15 0.768 0.884
IL4R rs1805010 G G 0.48:0.48 1.01 0.90 - 1.14 0.827 0.899
ICAM1 rs5491 T T 0.07:0.06 1.03 0.80 - 1.31 0.828 0.899
UGB rs3741240 A A 0.43:0.43 1.03 0.89 - 1.13 0.965 0.977
NOS2A rs1137933 T T 0.13:0.13 1.00 0.84 - 1.19 0.97 0.977
GC rs4588 A A 0.32:0.32 1.00 0.88 - 1.14 0.977 0.977
OR was calculated using a reference allele that resulted in an OR >1. P value and FDR adjusted for age, sex, body mass index and hypertension status in additive
model of inheritance.
FDR = false discovery rate; MAF =minor allele frequency.
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might be related to stroke risk. First, it may be the direct
consequence of atherosclerosis development. The eotaxin
gene and protein are over expressed in human atheroscler-
osis [17]. Vascular smooth muscle cells (VSMCs) [18] and
endothelium [19] in human atheroma prominently express
eotaxin, suggesting that eotaxin contributes to the pro-
gression of atherosclerosis. Second, increased eotaxin
levels can mirror the development of inflammatory
responses in heart and brain. Farahi et al. reported that
circulating eotaxin levels were increased in patients with
coronary artery disease [15].
To explore the influence of inflammatory genes on is-
chemic stroke in the hypertension and non-hypertension
groups, we stratified study subjects by their hypertension
status and found that CCR2 rs1799864 and CCR5
rs1799987 polymorphisms were associated with ischemic
stroke in the hypertensive group, and CCL11 rs3744508,
LTC4S rs730012, FCER1B rs569108, TGFB1 rs1800469
and LTA rs909253 were associated with ischemic stroke
in the non-hypertensive group.
CCR2 rs1799864, a SNP causing an isoleucine-for-
valine substitution at position 64 in the CCR2 receptor
on chromosome 3, was found to be associated with is-
chemic cardiomyopathy and myocardial infarction in
Czech populations [20,21]. And in an African-American
population from the Johns Hopkins Sibling and Family
Heart Study, it was reported that the combination of
homozygotic or heterozygote CCR2 rs1799864 genotype
and monocyte chemoattractant protein 1 (MCP-1)
rs2857656 homozygous genotype was associated with a
particularly high prevalence of carotid artery plaque
[22]. Chemokine receptor 2 (CCR2) is the receptor for
MCP-1. Recent studies have indicated that MCP-1 and
CCR2 could have an important role in regulating blood–
brain barrier permeability. An animal study had indi-
cated that a lack of CCR2 greatly reduced brain edema
formation and BBB disruption, as well as decreasing
leukocyte infiltration, and CCR2−/− mice had decreased
expression of a wide range of proinflammatory cytokines
during reperfusion [23]. Polymorphism CCR5 rs1799987
is located at position 59,029 in the promoter region of
CCR5 gene. The A allele of the SNP is associated with
susceptibility to diabetic nephropathy [24]. Chemokine
receptor 5 (CCR5) is the receptor for expressed on regu-
lated on activation, normal T cell expressed and secreted
(RANTES). RANTES was found as a mediator of cere-
bral ischemia-reperfusion (I/R) induced blood–brain
barrier disruption, tissue injury, and the inflammatory
and prothrombogenic phenotype assumed by the cere-
bral microvasculature after focal I/R [25]. In our study,
CCR2 rs1799864 and CCR5 rs1799987 were associated
with ischemic stroke only in the hypertensive group. We
tested the interaction between the polymorphisms and
hypertension status, and observed no relationship be-
tween them. A possible explanation is that in conditions
of high blood pressure, patients carrying risk allele(s)
suffer from cerebrovascular accident more than others
due to direct or indirect effects of CCR2/CCR5 on
blood–brain barrier and blood vessel of brain.
CCL11, CCR2 and CCR5 belong to the CC family of
chemokines. CC chemokines and their receptor poly-
morphisms have been shown to be associated with a
number of infection or inflammation-related disease
states, such as atherosclerosis [26]. To the best of our
knowledge, our study is the first to demonstrate the as-
sociation of CCL11, CCR2 and CCR5 genetic poly-
morphisms with the risk of ischemic stroke in a Chinese
population. CC chemokines may play an important role
Table 3 Single nucleotide polymorphisms (SNPs) achieving P <0.05 for association with ischemic stroke based on
hypertension-stratified population
Gene rsID Minor allele Risk allele MAF, control:case OR 95% CI P value FDR
Non-hypertension
CCL11 rs4795895 A G 0.07:0.05 1.57 1.05 - 2.66 0.032 0.202
CCL11 rs3744508 A A 0.10:0.16 1.64 1.20 - 2.25 0.002 0.076
LTA rs909253 G G 0.39:0.45 1.29 1.03 - 1.60 0.024 0.182
LTC4S rs730012 C C 0.11:0.16 1.55 1.13 - 2.12 0.007 0.086
TGFB1 rs1800469 C C 0.46:0.46 1.30 1.07 - 1.59 0.009 0.086
FCERB1 rs569108 G G 0.12:0.17 1.49 1.11 - 2.00 0.009 0.086
Hypertension
CCL11 rs4795895 A G 0.07:0.05 1.45 1.05 - 1.99 0.023 0.291
CCR2 rs1799864 A A 0.23:0.28 1.26 1.06 - 1.49 0.008 0.152
CCR5 rs1799987 A A 0.43:0.48 1.23 1.06 - 1.42 0.007 0.152
Non-hypertension: cases = 397 controls = 347; hypertension: cases = 727 controls = 816. OR was calculated using a reference allele that resulted in an OR >1.
P value and FDR adjusted for age, sex and body mass index in additive model of inheritance.
FDR = false discovery rate; MAF =minor allele frequency.
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in both the etiology and pathophysiology of ischemic
stroke; the functional relevance of these SNPs to ische-
mic stroke remains to be further elucidated and CC che-
mokines could represent promising therapeutic targets
in primary and secondary prevention of ischemic stroke.
In our study TGFB1 rs1800469, LTC4S rs730012 and
LTA rs909253 were associated with ischemic stroke in
the non-hypertensive group, which is in line with previ-
ous reports [9,27-30], although these findings drew from
different ethnic populations and different stroke sub-
types. Transforming growth factor β (TGFB) is a pleio-
tropic cytokine with a diversity of effects, such as
inducing or facilitating vascular stenosis and thrombo-
genesis [31,32]. TGFB1 rs1800469 polymorphism is
located in the promoter region and considered possible
modulator of expression of TGF-β1 gene and levels. A
case–control study had found an increased risk of stroke
associated with the risk allele of the rs1800469 in a
population from The Netherlands [27]. The rs730012
variant of leukotrieneC4 Synthase (LTC4S) upregulates
LTC4S mRNA expression, increasing the synthesis of
proinflammatory leukotrienes [28]. One study found that
the LTC4S rs730012 variant contributed to large vessel
stroke risk in children with sickle cell anemia [29]. Our
previous study, a meta-analysis of association of candi-
date polymorphisms and ischemic stroke in six popula-
tions, indicated LTA rs909253 was associated with
increased risk for ischemic stroke in normotensive sub-
jects but not in hypertensive ones [9]. This is in con-
cordance with the present report.
The β subunit of high affinity IgE receptor (FCER1B)
is a critical component of the IgE receptor, serving as a
chaperone to promote assembly and expression and a
strong amplifier of IgE-mediated signals [33]. The
FCER1B rs569108 G allele was found to have an associ-
ation with the development of allergic asthma in a Chin-
ese population [30]. In our study, the G allele of
rs569108 increased the risk of ischemic stroke in non-
hypertensive subjects. To explore the role of FCER1B
polymorphism in pathogenesis of ischemic stroke, more
genetic and functional studies will be needed.
There were five SNPs identified in the non-
hypertension group and two SNPs in the hypertension
group, however there were many more patients in the
hypertension group. One possible explanation is that in
the non-hypertensive group, the effect of genetic vari-
ation in inflammation gene may be easier to discern.
Clinical and experimental studies have reported that
hypertension itself is a chronic, low-grade inflammatory
process [34]. High blood pressure levels are associated
with an increase in circulating levels of inflammation
markers that can reflect a vascular inflammatory process
[35]. Hypertension could be a stronger factor causing in-
flammatory process. Therefore, it is possible that in the
hypertensive group the genetic influence of inflamma-
tory polymorphisms is concealed. Another possible ex-
planation is that different ischemic stroke subtypes may
occur in the different groups stratified by hypertensive
status, and stratification could result in a more homoge-
neous population. According to Arboix et al.’s research
[13], hypertension was the main cardiovascular risk fac-
tor only for lacunar and atherothrombotic infarction. In
the present study, different significant SNPs were
observed in the hypertensive and non-hypertensive
groups, indicating that these polymorphisms may be
associated with different subtypes of ischemic stroke, al-
though we could not further define the subtypes. To the
best of our knowledge, there is no study with the same
design as ours, although hundreds of genetic studies of
ischemic stroke have been performed in different geo-
graphic and ethnic populations. The ambiguous defin-
ition and stratification of ischemic stroke subtypes may
be a major reason why no confirmed inflammatory gen-
etic factor was found despite so many research projects
on the genetics of ischemic stroke.
There are limitations to our study. First, the current
study was a retrospective study, and the included stroke
patients were stroke survivors. It could not exclude pos-
sible selection bias. Secondly, the cases were not further
diagnosed with stroke subtypes, which may confound
the results. Thirdly, due to the limitations of the study
scope we did not collect information on subjects’ dia-
betes status, hypercholesterolemia, and coronary artery
disease, as well as plasma concentrations of inflamma-
tory markers, which play an important role in the devel-
opment of ischemic stroke. Also, smoking status was not
included in the multivariable analyses. Finally, the results
from this study have not been replicated, and should be
further validated by a carefully designed study.
Conclusions
The current study made a survey of inflammatory gene
polymorphisms in examining the risk for ischemic
stroke. The results were largely concordant with previ-
ous knowledge of inflammation and vascular diseases.
Our study demonstrated CCL11 rs4795895 is associated
with ischemic stroke after adjusting for multiple testing.
We also found five SNPs were associated with ischemic
stroke in the non-hypertensive group and two SNPs
were associated with ischemic stroke in the hypertensive
group. These results collectively showed that inflamma-
tory genetic variants were significantly associated with
increased risk of ischemic stroke, particularly in non-
hypertensive individuals. Additional studies in larger
populations will be needed to confirm the relationship
of inflammatory polymorphisms to stroke and its
subtypes.
Zhao et al. Journal of Neuroinflammation 2012, 9:162 Page 6 of 8
http://www.jneuroinflammation.com/content/9/1/162
Additional file
Additional file 1: Table S1. Risk allele frequencies, minor allele
frequencies and Hardy-Weinberg equilibrium P values for the genetic
polymorphisms in the Stroke Hypertension INvestigation IN Genetics
(SHINING) study.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
This study was supported by the Beijing Hypertension League Institute, in
part through the National Infrastructure Program of Chinese Genetic
Resource (2005DKA21300) and an unrestricted educational grant from F.
Hoffmann-La Roche. We thank Ms Wei Zhang, Jian Li, and Jinli Xing for their
excellent technical assistance.
Author details
1Department of Epidemiology, Public Health School, Harbin Medical
University, Heilongjiang, China. 2Laboratory of Human Genetics, Beijing
Hypertension League Institute, Beijing, China. 3The First Affiliated Hospital,
Medical College of Shantou University, Shantou, China. 4Fuwai Hospital,
Chinese Academy of Medical Sciences, Beijing, China.
Authors’ contributions
NZ, XL, YW carried out the molecular genetic studies and drafted the
manuscript. MT participated in the sequence alignment. LY, LM, SW, HZ, LL
participated in the design of the study. XL, JL participated in the statistical
analysis. XW and JZ designed the study, participated in its design and
coordination, and drafted the manuscript. All authors read and approved the
final manuscript.
Received: 28 September 2011 Accepted: 6 July 2012
Published: 6 July 2012
References
1. Bonita R, Mendis S, Truelsen T, Bogousslavsky J, Toole J, Yatsu F: The global
stroke initiative. Lancet Neurol 2004, 3:391.
2. Zhang LF, Yang J, Hong Z, Yuan GG, Zhou BF, Zhao LC, Huang YN, Chen J,
Wu YF: Proportion of different subtypes of stroke in China. Stroke 2003,
34:2091–2096.
3. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan
S, Islam S, Pais P, McQueen MJ: Risk factors for ischaemic and
intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE
study): a case–control study. Lancet 2010, 376:112–123.
4. Muir KW, Tyrrell P, Sattar N, Warburton E: Inflammation and ischaemic
stroke. Curr Opin Neurol 2007, 20:334.
5. Flex A, Gaetani E, Papaleo P, Straface G, Proia AS, Pecorini G, Tondi P, Pola P,
Pola R: Proinflammatory genetic profiles in subjects with history of
ischemic stroke. Stroke 2004, 35:2270–2275.
6. Zee RYL, Ridker PM: Polymorphism in the human C-reactive protein (CRP)
gene, plasma concentrations of CRP, and the risk of future arterial
thrombosis. Atherosclerosis 2002, 162:217–219.
7. Yoshida M, Takano Y, Sasaoka T, Izumi T, Kimura A: E-selectin
polymorphism associated with myocardial infarction causes enhanced
leukocyte-endothelial interactions under flow conditions. Arterioscler
Thromb Vasc Biol 2003, 23:783–788.
8. Rubattu S, Volpe M, Kreutz R, Ganten U, Ganten D, Lindpaintner K:
Chromosomal mapping of quantitative trait loci contributing to stroke in
a rat model of complex human disease. Nat Genet 1996, 13:429–434.
9. Wang X, Cheng S, Brophy VH, Erlich HA, Mannhalter C, Berger K, Lalouschek
W, Browner WS, Shi Y, Ringelstein EB: A meta-analysis of candidate gene
polymorphisms and ischemic stroke in 6 study populations. Association
of lymphotoxin-alpha in nonhypertensive patients. Stroke 2009,
108:524587–v524581. STROKEAHA.
10. Cordell HJ, Clayton DG: Genetic association studies. Lancet 2005,
366:1121–1131.
11. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical
and powerful approach to multiple testing. Journal of the Royal Statistical
Society Series B (Methodological) 1995, 289–300.
12. Smith NL, Hindorff LA, Heckbert SR, Lemaitre RN, Marciante KD, Rice K,
Lumley T, Bis JC, Wiggins KL, Rosendaal FR: Association of genetic
variations with nonfatal venous thrombosis in postmenopausal women.
JAMA 2007, 297:489.
13. Arboix A, Roig H, Rossich R, Martinez E, Garc-Eroles L: Differences between
hypertensive and non-hypertensive ischemic stroke. Eur J Neurol 2004,
11:687–692.
14. Nakamura H, Luster AD, Nakamura T, In KH, Sonna LA, Deykin A, Israel E,
Drazen JM, Lilly CM: Variant eotaxin: its effects on the asthma phenotype.
J Allergy Clin Immunol 2001, 108:946–953.
15. Farahi N, Cowburn AS, Upton PD, Deighton J, Sobolewski A, Gherardi E,
Morrell NW, Chilvers ER: Eotaxin-1/CC chemokine ligand 11: a novel
eosinophil survival factor secreted by human pulmonary artery
endothelial cells. J Immunol 2007, 179:1264.
16. Colobran R, Pujol-Borrell R, Armengol M, Juan M: The chemokine network.
II. On how polymorphisms and alternative splicing increase the number
of molecular species and configure intricate patterns of disease
susceptibility. Clin Exp Immunol 2007, 150:1–12.
17. Haley KJ, Lilly CM, Yang JH, Feng Y, Kennedy SP, Turi TG, Thompson JF,
Sukhova GH, Libby P, Lee RT: Overexpression of eotaxin and the CCR3
receptor in human atherosclerosis: using genomic technology to identify
a potential novel pathway of vascular inflammation. Circulation 2000,
102:2185.
18. Kodali RB, Kim WJH, Galaria II, Miller C, Schecter AD, Lira SA, Taubman MB:
CCL11 (Eotaxin) induces CCR3-dependent smooth muscle cell migration.
Arterioscler Thromb Vasc Biol 2004, 24:1211–1216.
19. Cheng SS, Lukacs NW, Kunkel SL: Eotaxin/CCL11 suppresses IL-8/CXCL8
secretion from human dermal microvascular endothelial cells. J Immunol
2002, 168:2887.
20. Ortlepp JR, Vesper K, Mevissen V, Schmitz F, Janssens U, Franke A, Hanrath
P, Weber C, Zerres K, Hoffmann R: Chemokine receptor(CCR 2) genotype is
associated w it h myo-cardial infarction and heart failure in pa-tients
under 65 years of age. J Mol Med 2003, 81:363–367.
21. Petrkova J, Cermakova Z, Drabek J, Lukl J, Petrek M: CC chemokine
receptor (CCR)2 polymorphism in Czech patients with myo-cardial
infarction. Immunol Lett 2003, 88:53–55.
22. Nyquist PA, Winkler CA, McKenzie LM, Yanek LR, Becker LC, Becker DM:
Single nucleotide polymorphisms in monocyte chemoattractant protein-
1 and its receptor act synergistically to increase the risk of carotid
atherosclerosis. Cerebrovasc Dis 2009, 28(2):124–130.
23. Dimitrijevic OB, Stamatovic SM, Keep RF, Andjelkovic AV: Absence of the
chemokine receptor CCR2 protects against cerebral ischemia/reperfusion
injury in mice. Stroke 2007, 38:1345–1353.
24. Mooyaart AL, Valk EJJ, van LA Es, Bruijn JA, de Heer E, Freedman BI, Dekkers
OM, Baelde HJ: Genetic associations in diabetic nephropathy: a meta-
analysis. Diabetologia 2011, 54:544–553.
25. Terao S, Yilmaz G, Stokes KY, Russell J, Ishikawa M, Kawase T, Granger DN:
Blood cell-derived RANTES mediates cerebral microvascular dysfunction,
inflammation, and tissue injury after focal ischemia Creperfusion. Stroke
2008, 39:2560–2570.
26. Mirabelli-Badenier M, Braunersreuther V, Viviani GL, Dallegri F, Quercioli A,
Veneselli E, Mach F, Montecucco F: CC and CXC chemokines are pivotal
mediators of cerebral injury in ischaemic stroke. Thromb Haemost 2011,
105:105.
27. Sie MPS, Uitterlinden AG, Bos MJ, Arp PP, Breteler M, Koudstaal PJ, Pols HAP,
Hofman A, van Duijn CM, Witteman J: TGF-{beta}1 polymorphisms and
risk of myocardial infarction and stroke. Stroke 2006, 37:2667–2671.
28. Iovannisci DM, Lammer EJ, Steiner L, Cheng S, Mahoney LT, Davis PH, Lauer
RM, Burns TL: Association between a leukotriene C4 synthase gene
promoter polymorphism and coronary artery calcium in young women.
Arterioscler Thromb Vasc Biol 2007, 27:394–399.
29. Hoppe C, Klitz W, D’Harlingue K, Cheng S, Grow M, Steiner L, Noble J,
Adams R, Styles L: Confirmation of an association between the TNF
(−308) promoter polymorphism and stroke risk in children with sickle
cell anemia. Stroke 2007, 107:483115–v483111. STROKEAHA.
30. Cui T, Wang L, Wu J, Xie J: The association analysis of FcepsilonRIbeta
with allergic asthma in a Chinese population. Chin Med J (Engl), 2003:116.
Zhao et al. Journal of Neuroinflammation 2012, 9:162 Page 7 of 8
http://www.jneuroinflammation.com/content/9/1/162
31. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Weir L: Expression of
transforming growth factor-1 is increased in human vascular restenosis
lesions. J Clin Invest 1992, 90:1582–1592.
32. Schulick AH, Taylor AJ, Zuo W, Qiu CB, Dong G, Woodward RN, Agah R,
Roberts AB, Virmani R, Dichek DA: Overexpression of transforming growth
factor- β1 in arterial endothelium causes hyperplasia, apoptosis, and
cartilaginous metaplasia. Proc Natl Acad Sci U S A 1998, 95:6983–6988.
33. Donnadieu E, Jouvin MH, Kinet JP: A second amplifier function for the
allergy-associated Fc(e)RI- β subunit. Immunity 2000, 12:515–523.
34. Savoia C, Schiffrin EL: Inflammation in hypertension. Curr Opin Nephrol
Hypertens 2006, 15:152.
35. Cachofeiro V, Miana M, Martin-Fernandez B, Ballesteros S, Balfagon G, Laher
V: Inflammation: a link between hypertension and atherosclerosis.
Current Hypertension Reviews 2009, 5:40–48.
doi:10.1186/1742-2094-9-162
Cite this article as: Zhao et al.: Association of inflammatory gene
polymorphisms with ischemic stroke in a Chinese Han population.
Journal of Neuroinflammation 2012 9:162.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zhao et al. Journal of Neuroinflammation 2012, 9:162 Page 8 of 8
http://www.jneuroinflammation.com/content/9/1/162
